Research programme: antibody encoded oncolytic viruses - BioInvent/Transgene

Drug Profile

Research programme: antibody encoded oncolytic viruses - BioInvent/Transgene

Latest Information Update: 13 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioInvent International; Transgene
  • Class Antibodies; Antineoplastics; Oncolytic viruses
  • Mechanism of Action Cell death stimulants; Cytotoxic T-lymphocyte antigen 4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 06 Dec 2017 BioInvent International and Transgene enter a research collaboration to develop antibody encoded oncolytic viruses for Solid tumours
  • 06 Dec 2017 Preclinical trials in Solid tumours in France and Sweden (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top